WFS1 Gene Wolfram Syndrome Type 1 Genetic Test in Dubai | AED 2800

Executive Summary & Core Metrics

The WFS1 Gene Wolfram Syndrome Type 1 Genetic Test employs next-generation sequencing (NGS) to detect pathogenic variants in the entire coding region of the WFS1 gene, achieving a diagnostic sensitivity exceeding 99.9%. This analysis supports early identification of DIDMOAD syndrome (diabetes insipidus, diabetes mellitus, optic atrophy, deafness) and enables proactive clinical management. Testing is performed under ISO-accredited protocols with VIP mobile phlebotomy and temperature-controlled cold-chain home collection available daily from 8 AM to 11 PM.

Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing.
Premium Logistics: Hospital-Grade Home Collection via ISO Certified Cold-Chain and VIP Mobile Phlebotomy.
Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation.
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.

Test Overview & Methodology

The WFS1 Gene Wolfram Syndrome Type 1 Genetic Test screens the complete coding region of the WFS1 gene using next-generation sequencing, enabling early detection of mutations linked to DIDMOAD syndrome. This assay covers all exons and flanking intronic regions for comprehensive variant identification. Advanced bioinformatic pipelines filter and classify variants according to ACMG guidelines, ensuring high-confidence reporting of pathogenic, likely pathogenic, and variants of uncertain significance.

Feature	Our NGS Test	Sanger Sequencing (Alternative)
Precision	>99.9% sensitivity for all exonic mutations	High specificity but misses deep intronic variants
Methodology	Next-Generation Sequencing (NGS) with full bioinformatic analysis	Targeted Sanger sequencing of selected exons only
Turnaround Time	3 to 4 Weeks	4–6 Weeks (often requires reflex testing)

Physician Insight & Safety Protocols

Ms. Lina Osama Zaki Quteineh | Consultant Medical Genetics | DHA Registration ID: 9294403: “Genetic testing for WFS1 provides families with a definitive diagnosis and a roadmap for managing the multisystem manifestations of Wolfram syndrome. I encourage patients to review their results alongside a thorough clinical evaluation and family history to ensure the most accurate interpretation and personalized care plan.”

⚠️ Medication Advisory

Do not discontinue prescribed medication without consulting your doctor. Genetic results alone do not replace ongoing clinical care. Always follow your treating physician’s guidance regarding insulin, antihyperglycemic agents, or other therapies.

Patient Safety – Exclusion Criteria & Red Flags

Exclusion: Inability to provide informed consent; refusal of pre-test genetic counselling; hemodynamic instability preventing blood draw.
Emergency Red Flags: Sudden severe vision loss, new-onset diabetic ketoacidosis, severe dehydration – seek immediate medical attention regardless of test status.

Patient FAQ & Clinical Guidance

1. What is the WFS1 Gene Wolfram Syndrome Type 1 Genetic Test?

This test uses next-generation sequencing to detect pathogenic mutations in the WFS1 gene, which causes Wolfram syndrome type 1 (DIDMOAD). It analyzes all exons and splice sites for variants associated with diabetes insipidus, diabetes mellitus, optic atrophy, and deafness. The assay is performed on whole blood or dried blood spot with diagnostic sensitivity exceeding 99.9%.

2. How should I prepare for the WFS1 gene test?

No fasting is required. Simply provide a whole blood sample or dried blood spot on FTA card. Our home collection team will guide you through the painless process. No special diet or medication adjustments are needed, but please inform us of any anticoagulants you take. Pre-test genetic counselling is available and recommended.

3. How long does it take to get results and what support is offered?

Results are available in 3 to 4 weeks and include expert telephonic clinical guidance to interpret findings in the context of your personal and family medical history. Reports are delivered via a secure online portal, and our clinical team can schedule a follow-up consultation to discuss the implications and recommend next steps.

UAE Regulatory & Data Privacy Adherence

Regulatory Compliance & Data Protection: This service strictly adheres to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent follow Federal Decree-Law No. 4 of 2016 on Medical Liability. All genetic data is encrypted, access-controlled, and processed solely for diagnostic purposes. Your privacy is protected under UAE law.

Clinical & Logistical Metadata

Test Name	WFS1 Gene Wolfram Syndrome Type 1 Genetic Test
Price (AED)	2,800 AED
Turnaround Time	3 to 4 Weeks
Sample Type / Matrix	Whole Blood, Dried Blood Spot (FTA Card)
Methodology Used	Next-Generation Sequencing (NGS) with Full Bioinformatic Analysis
ICD-10-CM Code	E13.8
LOINC Code	92765-6
DHA Facility License & Laboratory Address	DHA Facility License No: 1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE \| Corporate Lab: DNA Labs UAE